Coherus BioSciences Inc. (NASDAQ:CHRS) changes shares on Friday trading session, with a change of -0.37% or -$0.06 shares. The trading starts at $16.57 and closed at $16.14 throughout the day. The trading session low price was $15.57 and day high was $16.59 on Friday, June 12. After the session, the Healthcare sector daily volume shifted to 1.75 million while its average volume is 1.84M. In other hand, the CHRS market cap reached to $1.14B. While, its current target price is $16.08 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -14.56% and down -1.83% for month. Its quarterly performance was 7.56% above, while its half year performance is down -10.17%. CHRS yearly performance stood at negative -11.89% and fall -10.69% for year-to-date. Current recommendation for Coherus BioSciences Inc. is 1.80.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. CHRS EPS (TTM) for 12-month is 1.93. EPS for this year is 138.10%, while for the next year its value is 1.11. Sales growth for the current quarter is 0.36 while its EPS Q/Q reached 265.20%. It has an EPS of 16.20% up for past five years and for the next five years will be up 23.00%.
Let’s take a look on the analyst recommendations on CHRS for the current month and previous month. For the current month, 8 of 9 analysts recommend stock as Buy while 0 as Sell, 1 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $26.00-$35.00. Average target price for CHRS was reached at $31.11.
Temasek Holdings (Private) Limited, Blackrock Inc. and JP Morgan Chase & Company are the top three holders in Coherus BioSciences Inc. (CHRS) stock. On Mar 30, 2020, Temasek Holdings (Private) Limited has 7.38 million shares which valued 119.72 million. On Mar 30, 2020, Blackrock Inc. owned 5.45 million shares which valued at 88.44 million. On Mar 30, 2020, JP Morgan Chase & Company has a total of 4.12 million shares which valued at 66.9 million. In the end, JP Morgan Chase & Company have 5.82% shares outstanding of Coherus BioSciences Inc. (CHRS) on Mar 30, 2020. The insider ownership moved to 0.50%.
The company posted an EPS (TTM) of 1.93. According to the most recent quarter report on (Jun 2020), 7 analysts estimated an average EPS of 0.29, while 0.32 EPS posted a year ago period. Analyst Estimated EPS for CHRS published in the report was 0.2-0.39 during the same period. Comparing with last year, the average estimated EPS was 0.32 which is lower than 0.48 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for CHRS fall -12.43% for period of 200 days. SMA for 50 days was -4.56% which is showing red signal, while SMA-20 was -9.67%. The moving average value for Coherus BioSciences Inc. (CHRS) is 17.80 and 17.35 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in CHRS stock. On May 20, Viret Jean-Frederic, Chief Financial Officer, sold 1,278 trading shares at the cost of $17.66, which valued at 22569.0. On May 18, Anicetti Vincent R, Chief Operating Officer, sold 3,093 shares at the cost of $17.17, with total shares of 48,556. On Apr 20, Anicetti Vincent R, Chief Operating Officer, sold 5,150 shares at the cost of 17.00. After this transaction, Anicetti Vincent R total shares reached to 47,846 which valued at 87550.0.